title: Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center.
abstract: Allogeneic hematopoietic stem cell transplantation (ASCT) representes a potentially curative approach for patients with relapsed or refractory acute myeloid leukemia (AML). We report the outcome of relapsed/refractory AML patients treated with ASCT.
  A retrospective cohort from 1994 to 2013 that included 61 patients with diagnosis of relapsed/refractory AML. Outcomes of interest were transplant-related mortality (TRM), incidence of acute and chronic graft-versus-host disease (GVHD), relapse incidence, progression-free survival (PFS) and overall survival (OS). Statistical significance was set at p<0.05.
  The median age was 61 years (range 1 to 65). The cumulative incidence of 90 days, 1 year, and 3 years TRM were 60%, 26.7%, and 13.3%, respectively (p<0.001). The incidence of relapse was 21.7% at 1 year, 13% at 3 years, and 8.7% at 5 years. Median OS was estimated to be 8 months (95CI 3.266-12.734) and median PFS, 3 months (95CI 1.835-4.165).
  In our cohort, TRM in first years after ASCT remains considerable, but ASCT in this setting seems to be a good choice for AML patients with active disease. However, novel approaches are needed to reduce TRM and relapse in this set of patients.
authors.affiliation: Professor of Medicine and Clinical Oncology, Instituto Português de Oncologia Francisco Gentil (IPO-Porto) and Universidade do Algarve, Faro, Portugal.
authors.forename: Ramon Andrade Bezerra
authors.initials: RA
authors.lastname: De-Mello
authors.affiliation: Oncologist, IPO-Porto, Porto, Portugal.
authors.forename: Carlos
authors.initials: C
authors.lastname: Pinho-Vaz
authors.affiliation: Hematologist, IPO-Porto, Porto, Portugal.
authors.forename: Rosa
authors.initials: R
authors.lastname: Branca
authors.affiliation: Hematologist, IPO-Porto, Porto, Portugal.
authors.forename: Fernando
authors.initials: F
authors.lastname: Campilho
authors.affiliation: Immune Hematology Therapist, IPO-Porto, Porto, Portugal.
authors.forename: Maria
authors.initials: M
authors.lastname: Rosales
authors.affiliation: Immune Hematology Therapist, IPO-Porto, Porto, Portugal.
authors.forename: Susana
authors.initials: S
authors.lastname: Roncon
authors.affiliation: Director of the Bone Marrow Transplantation Service, IPO-Porto, Porto, Portugal.
authors.forename: António
authors.initials: A
authors.lastname: Campos-Júnior
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D018450:Disease Progression; D018572:Disease-Free Survival; D023381:Endpoint Determination; D005260:Female; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality*; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000401:mortality* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013997:Time Factors; D014184:Transplantation, Homologous / Q000379:methods / Q000401:mortality; D016896:Treatment Outcome; D055815:Young Adult